NMRA NEUMORA THERAPEUTICS INC

Neumora Therapeutics to Participate in Upcoming Conferences in May

Neumora Therapeutics to Participate in Upcoming Conferences in May

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May:

  • BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.

  • 2024 RBC Capital Markets Global Healthcare Conference: Members of management will participate in a fireside chat on Wednesday, May 15, 2024, at 9:00 AM ET in New York, NY.

A live webcast of each event will be available on the events and presentations section of the Company’s website at . A replay of the webcasts will be available following the completion of the event and will be archived for up to 30 days.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:

Helen Rubinstein

315-382-3979



EN
06/05/2024

Underlying

NMRANEUMORA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUMORA THERAPEUTICS INC

 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacapr...

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics ...

May 14, 2024 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Reports First Quarter 2024 Financial Results and ...

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi...

May 7, 2024 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Participate in Upcoming Conferences in May

Neumora Therapeutics to Participate in Upcoming Conferences in May WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.2024 RBC Capital Markets Global ...

May 6, 2024 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company’s M4 PAM franchise. The clinical hold determina...

April 15, 2024 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 11:00 a.m. ET. A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at . A replay of the webcast will be available following the completion of...

March 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch